In MedTech, some people shape the market not through budget authority, but through professional reputation. A chief physician speaking at a national medical conference. A physician publishing in leading specialty journals. A clinician showing peers how they perform a procedure.
These are key opinion leaders. If they're missing from your commercial strategy, you're fighting an invisible headwind.
What a KOL actually is and what they aren't
A KOL isn't a spokesperson or a paid promoter. They're someone whose scientific or clinical expertise is respected enough that other physicians listen to their recommendations without being paid to do so.
That's the difference from influencer marketing: credibility comes from expertise, not reach.
National / international KOLs
Conference speakers, journal editors and professors. A small number of people with enormous influence on approval committees, treatment guidelines and international adoption.
Goal: strategic partnerships, clinical studies
Regional KOLs
Chief physicians at teaching hospitals, accredited trainers and speakers at regional medical societies. They can be decisive in driving adoption within their own hospital and regional network.
Goal: training, product demonstrations, reference visits
Local early adopters
Engaged practitioners or hospital physicians who are open to innovation. They may not have a broad network yet, but they're willing to try new approaches and recommend them internally.
Goal: first clinical users, feedback providers, internal advocates
How to build a KOL strategy
Identification
Who publishes? Who speaks at conferences? Who trains others? Look at bibliometrics, conference programs, and medical societies.
Engagement
Advisory boards, clinical studies, and proctoring programs. The principle is always the same: create scientific value for the KOL, not just revenue for your company.
Activation
Conference presentations, training, webcasts, and publications. KOLs speak to their professional community, not on behalf of the brand.
"KOLs don't want to sell products. They want to serve their profession. The question is: how does your product help them do that?"
The KOL's role in the buying process
KOLs influence the market on three levels. They help set clinical standards and define what is considered state of the art. They influence procurement decisions and they train colleagues.
When launching a new product, you need at least one T1 KOL at every stage who can say: "I've used it and it works."
Inside a hospital, it typically works like this: the T2 KOL runs the demo at their hospital. Visitors from other hospitals see the product in use. Questions come up. Inquiries follow.
Without a T2 KOL as a reference user, there are no demos, no reference visits, and no follow-on deals.
Common mistakes in KOL strategy
| Mistake | Consequence |
|---|---|
| Bringing KOLs in too late, only after market approval | No feedback during product development and no sense of ownership at launch |
| Treating KOLs purely as a sales tool | The relationship breaks down when there is no clear value for the KOL |
| Focusing only on T1 KOLs | Local adoption stalls because no regional network has been built |
| No clear compliance rules | Transparency violations, such as disclosure or Sunshine Act violations, can have legal consequences |
| Failing to document KOL relationships | Relationships are lost when employees leave and competitors can step in |
A KOL isn't a channel. They're a partner.
The relationship has to create scientific and professional value for them, not just financial value. Understand that and you build a network that remains valuable even when the product changes.